Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13164MR)

This product GTTS-WQ13164MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13164MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12436MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ14739MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ14454MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ1591MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ6616MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ1312MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ8142MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ2542MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW